Metabolic Surgery as a Treatment Option for Type 2 Diabetes Mellitus: Surgical View
Purpose of Review
Type 2 diabetes mellitus (T2DM) is increasing in prevalence and associated with numerous metabolic complications leading to increased mortality and costs. Metabolic surgery, or surgery to treat T2DM and obesity, is effective at achieving remission from T2DM. This review discusses the most commonly used surgical options including the adjustable gastric band, the Roux-en-Y gastric bypass, the sleeve gastrectomy, and the biliopancreatic diversion with duodenal switch and their ability to treat and prevent T2DM.
There is an increasing body of literature that justifies the inclusion of metabolic surgery into the treatment algorithm for patients with obesity and T2DM. Metabolic procedures should be performed at centers that offer comprehensive treatment of metabolic disorders and have expertise in gastrointestinal surgery. The incremental improvement in the quality and safety of metabolic surgery has significantly reduced the risk of serious post-operative complications.
Metabolic surgery is a safe and effective treatment option for obese patients with T2DM.
KeywordsType 2 diabetes Gastric sleeve Adjustable gastric band Biliopancreatic diversion with duodenal switch Gastric bypass Metabolic surgery
Compliance with Ethical Standards
Conflict of Interest
Eric Rachlin and Carlos Galvani declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 10.Daigle CR, Brethauer SA, Tu C, Petrick AT, Morton JM, Schauer PR, et al. Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes. Surg Obes Relat Dis. 2018;14(5):652–7. https://doi.org/10.1016/j.soard.2018.01.008.CrossRefPubMedGoogle Scholar
- 11.Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25-7, 1991. Nutrition 1996;12(6):397–404Google Scholar
- 12.Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al. Delegates of the 2nd Diabetes Surgery Summit metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77. https://doi.org/10.2337/dc16-0236.CrossRefPubMedGoogle Scholar
- 13.Mechanick JI, Youdim A, Jones DB, Garvey WT, Hurley DL, MM MM, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(Suppl 1):S1–27. https://doi.org/10.1002/oby.20461.CrossRefGoogle Scholar
- 15.Aberle J, Freier A, Busch P, Mommsen N, Beil FU, Dannheim V, et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes Surg. 2009;19(11):1504–7. https://doi.org/10.1007/s11695-009-9940-5.CrossRefPubMedGoogle Scholar
- 16.Parrott J, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. Surg Obes Relat Dis. 2017;13(5):727–41. https://doi.org/10.1016/j.soard.2016.12.018.CrossRefPubMedGoogle Scholar
- 17.O'Brien PE, MacDonald L, Anderson M, Brennan L, Brown WA. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg. 2013;257(1):87–94. https://doi.org/10.1097/SLA.0b013e31827b6c02.CrossRefPubMedGoogle Scholar
- 20.Courcoulas AP, Belle SH, Neiberg RH, Pierson SK, Eagleton JK, Kalarchian MA, et al. Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial. JAMA Surg. 2015;150(10):931–40. https://doi.org/10.1001/jamasurg.2015.1534.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Rodríguez A, Mosti M, Sierra M, Pérez-Johnson R, Flores S, Dominguez G, et al. Small bowel obstruction after antecolic and antegastric laparoscopic Roux-en-Y gastric bypass: could the incidence be reduced? Obes Surg. 2010;20(10):1380–4. https://doi.org/10.1007/s11695-010-0164-5.CrossRefPubMedGoogle Scholar
- 26.Yan Y, Sha Y, Yao G, Wang S, Kong F, Liu H, et al. Roux-en-Y Gastric bypass versus medical treatment for type 2 diabetes mellitus in obese patients: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(17):e3462. https://doi.org/10.1097/MD.0000000000003462.CrossRefGoogle Scholar
- 27.•• Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. 2017;377(12):1143–55. https://doi.org/10.1056/NEJMoa1700459. This study demonstrates one of the longest follow-up periods, 12 years, for patients undergoing metabolic surgery. It demonstrates the long-term efficacy of metabolic surgery in achieving weight loss and decrease in obesity-associated comorbidities. CrossRefPubMedPubMedCentralGoogle Scholar
- 28.• Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016;151(11):1046–55. https://doi.org/10.1001/jamasurg.2016.2317. This prospective cohort study shows the durability of weight loss with metabolic surgery over time. CrossRefPubMedPubMedCentralGoogle Scholar
- 29.•• Kabir A, Mousavi S, Pazouki A. The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A systematic Review and Meta-Analysis. Curr Diabetes Rev. 2018 . https://doi.org/10.2174/1573399814666180403164529. This review looks at complication rates of various metabolic procedures.
- 32.Estimate of bariatric surgery numbers, 2011–2017. American Society for Metabolic and Bariatric Surgery, asmbs.org/resources/estimate-of-bariatric-surgery-numbers.Google Scholar
- 34.Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52. https://doi.org/10.1007/s11695-013-1066-0.CrossRefPubMedGoogle Scholar
- 37.Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Thiesen V, Fornari F. The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the Montreal Consensus. Ann Surg. 2010;251(2):244–8. https://doi.org/10.1097/SLA.0b013e3181bdff20.CrossRefPubMedGoogle Scholar
- 38.•• Peterli R, Wölnerhanssen BK, Vetter D, Nett P, Gass M, Borbély Y, et al. Laparoscopic sleeve gastrectomy versus Roux-Y-gastric bypass for morbid obesity-3-year outcomes of the prospective randomized Swiss Multicenter Bypass Or Sleeve Study (SM-BOSS). Ann Surg. 2017;265(3):466–73. https://doi.org/10.1097/SLA.0000000000001929. A randomized controlled trial comparing RYGB and SG over a 3 year period. CrossRefPubMedGoogle Scholar
- 39.•• Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51. https://doi.org/10.1056/NEJMoa1600869. A randomized controlled trial comparing medical management to RYGB to SG over a 5 year period. CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297–304. https://doi.org/10.1001/jama.2014.5988.CrossRefPubMedGoogle Scholar
- 42.Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258(4):628–36; discussion 636-7. https://doi.org/10.1097/SLA.0b013e3182a5034b.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.•• Salminen P, Helmiö M, Ovaska J, Juuti A, Leivonen M, Peromaa-Haavisto P, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319(3):241–54. https://doi.org/10.1001/jama.2017.20313. A randomized controlled trial comparing SG and RYGB over a 5-year period. CrossRefPubMedPubMedCentralGoogle Scholar
- 46.•• Melissas J, Stavroulakis K, Tzikoulis V, Peristeri A, Papadakis JA, Pazouki A, et al. Sleeve gastrectomy vs Roux-en-Y gastric bypass. Data from IFSO-European Chapter Center of Excellence Program. Obes Surg. 2017;27(4):847–55. https://doi.org/10.1007/s11695-016-2395-6. A large cohort study comparing SG and RYGB. CrossRefPubMedGoogle Scholar
- 47.• Risstad H, Søvik TT, Engström M, Aasheim ET, Fagerland MW, Olsén MF, et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015;150(4):352–61. https://doi.org/10.1001/jamasurg.2014.3579.CrossRefPubMedGoogle Scholar